Search

Fruquintinib

This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … Although [bevacizumab] is successful in sustaining target inhibition, mandatory intravenous dosing, immunogenicity, and the potential to induce autoimmune diseases hinder its clinical application.

Calcium alginate

Phenyltoloxamine

It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. … Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient.

Brensocatib

[A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813] … [A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation.

Meningococcal polysaccharide vaccine group Y

It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.

Aminoglutethimide

Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. … An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens.

Keyhole limpet hemocyanin

Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins. … Keyhole limpet hemocyanin is an immune modulator, given as a vaccine to help the body respond to cancer. A natural protein isolated from the marine mollusc keyhole limpet.

BNT162B2 Omicron (LP.8.1)

BNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19. … [L53723] It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2.[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025.

Mirikizumab

[L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with … [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023.

Florbetapir F-18

that plays a key role in Alzheimer's Disease pathogenesis. … The radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay.